132 related articles for article (PubMed ID: 38423635)
1. Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study.
Baudrexl J; Sakkas A; Pietzka S; Derka S; Vairaktari G; Scheurer M; Schramm A; Wilde F; Ebeling M
Anticancer Res; 2024 Mar; 44(3):1247-1270. PubMed ID: 38423635
[TBL] [Abstract][Full Text] [Related]
2. Sex-specific Real-World 5-year Overall Survival Rates for (Radio)chemotherapy, Targeted Therapy, and Combinations in Patients With Head and Neck Cancer.
Baudrexl J; Pietzka S; Scheurer M; Schramm A; Wilde F; Sakkas A; Derka S; Ebeling M
Anticancer Res; 2024 Jan; 44(1):267-286. PubMed ID: 38159994
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
5. Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer.
Koroukian SM; Booker BD; Vu L; Schumacher FR; Rose J; Cooper GS; Selfridge JE; Markt SC
JAMA Netw Open; 2023 Jan; 6(1):e2250030. PubMed ID: 36656585
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Bauman JE; Arias-Pulido H; Lee SJ; Fekrazad MH; Ozawa H; Fertig E; Howard J; Bishop J; Wang H; Olson GT; Spafford MJ; Jones DV; Chung CH
Oral Oncol; 2013 May; 49(5):461-7. PubMed ID: 23384718
[TBL] [Abstract][Full Text] [Related]
7. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany.
Morkramer L; Geitner M; Boeger D; Buentzel J; Kaftan H; Mueller AH; Ernst T; Guntinas-Lichius O
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2625-2635. PubMed ID: 33517469
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
11. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
12. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
14. [Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review].
Cherifi F; Rambeau A; Johnson A; Florescu C; Géry B; Babin E; Thariat J
Bull Cancer; 2019 Oct; 106(10):923-938. PubMed ID: 31324333
[TBL] [Abstract][Full Text] [Related]
15. Ibuprofen Reduces 5-Year Overall Survival of Head and Neck Cancer Patients With Immunotherapy - A Retrospective Case-controlled Real-World Data Analysis of 10,000 Patients.
Ebeling M; Derka S; Baudrexl J; Sakkas A; Scheurer M; Wilde F; Schramm A; Pietzka S
Anticancer Res; 2024 Jan; 44(1):313-322. PubMed ID: 38159991
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome.
Röhl L; Wellhausen J; Berszin M; Krücken I; Zebralla V; Pirlich M; Wiegand S; Dietz A; Wald T; Wichmann G
Front Immunol; 2023; 14():1237623. PubMed ID: 37849764
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
18. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
[TBL] [Abstract][Full Text] [Related]
20. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
